McAdam LLC Sells 1,224 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

McAdam LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,568 shares of the biopharmaceutical company’s stock after selling 1,224 shares during the quarter. McAdam LLC’s holdings in Gilead Sciences were worth $775,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Morgan Stanley boosted its holdings in shares of Gilead Sciences by 0.9% in the third quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock valued at $1,267,207,000 after buying an additional 158,794 shares during the period. Northern Trust Corp increased its position in shares of Gilead Sciences by 3.5% during the 3rd quarter. Northern Trust Corp now owns 14,922,488 shares of the biopharmaceutical company’s stock worth $1,118,291,000 after purchasing an additional 504,475 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in shares of Gilead Sciences by 10.8% in the 4th quarter. Pacer Advisors Inc. now owns 5,046,652 shares of the biopharmaceutical company’s stock valued at $408,829,000 after buying an additional 493,920 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Gilead Sciences by 12.5% in the 3rd quarter. AQR Capital Management LLC now owns 4,773,688 shares of the biopharmaceutical company’s stock valued at $357,740,000 after buying an additional 531,314 shares during the last quarter. Finally, Clearbridge Investments LLC increased its stake in shares of Gilead Sciences by 179.0% during the 3rd quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock worth $340,526,000 after purchasing an additional 2,915,141 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.29% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $65.94 on Tuesday. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. The stock has a market cap of $82.10 billion, a PE ratio of 183.17, a P/E/G ratio of 1.29 and a beta of 0.19. Gilead Sciences, Inc. has a 12-month low of $64.63 and a 12-month high of $87.86. The business’s 50-day moving average price is $71.16 and its two-hundred day moving average price is $76.17.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.37 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 3.82 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.67%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Analyst Ratings Changes

A number of equities analysts have weighed in on GILD shares. Barclays lowered their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research report on Monday. Cantor Fitzgerald decreased their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Wells Fargo & Company cut their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Oppenheimer restated an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research report on Friday, April 19th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $83.60.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.